Myriad's (MYGN) New Acquisition to Boost Precision Oncology Arm
Myriad(MYGN) Zacks Investment Research·2024-01-22 22:56
Myriad Genetics (MYGN) , a front-runner in genetic testing and precision medicine, recently announced its plans to acquire select assets from Intermountain Precision Genomics (IPG). This acquisition, including the Precise Tumor Test, the Precise Liquid Test and the Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory in St. George, UT, is set to close on Feb 1, 2024.The financial terms of the deal were not disclosed.The Deal and its BenefitsBy bringing the Precise Tumor and Precise Liquid ...